{"title": "PDF", "author": "PDF", "url": "https://www.fhi.no/globalassets/dokumenterfiler/rapporter/2016/legemiddelforbruket-i-norge-2011-2015-pdf.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "2011-2015 Utgitt av Nasjonalt folkehelseinstitutt Published by Norwegian Institute of Public Health Bestilling/Order: Kun tilgjengelig som PDF. Lastes ned fra www.fhi.no as PDF from HealthP. O. fra www.fhi.no /The report is available electronically in PDF-format only. It can be downloaded from www.fhi.no Consumption in Norway 2011-2015 (Legemiddelforbruket i Norge 2011-2015), Norwegian Institute of 2016:1 Tidligere utgaver/ Previous 1978: Legemiddelforbruket i Norge 1975 - 1977 1980: Legemiddelforbruket i Norge 1975 - 1979 1981: Legemiddelforbruket i Norge 1980 1982: Legemiddelforbruke t i Norge 1977 - 1981 1984: Legemiddelforbruket i Norge 1979 - 1983 1985: Legemiddelforbruket i Norge 1984 1986: Legemiddelforbruket i Norge 1981 - 1985 1987: Legemiddelforbruket i Norge 1986 1988: Legemiddelforbruket i Norge 1987 1989: Legemiddelforbruket i Norge 1984 - 1988 1990: Legemiddelforbruket i Norge 1989 1991: Legemiddelforbruket i Norge 1986 - 1990 1992: Legemiddelforbruket i Norge 1991 1993: Legemiddelforbruket i Norge 1988 - 1992 1994: Legemiddelforbruket i Norge 1989 - 1993 1995: Legemiddelfor bruket i Norge 1990 - 1994 1996: Legemiddelforbruket i Norge 1991 - 1995 1997: Legemiddelforbruket i Norge 1992 - 1996 1998: Legemiddelforbruket i Norge 1993 - 1997 1999: Legemiddelforbruket i Norge 1994 - 1998 2000: Legemiddelforbruket i Norge 1995 - 1999 2001: Legemiddelforbruket i Norge 1996 - 2000 2002: Legemiddelforbruket i Norge 1997 - 2001 2003: Legemiddelforbruket i Norge 1998 - 2002 2004: Legemiddelforbruket i Norge 1999 - 2003 2005: Legemiddelforbruket i Norge 2000 - 2004 2006: Legemiddelforbruket i Norge 2001 - 2005 2007: Legemiddelforbruket i Norge 2002 - 2006 2008: Legemiddelforbruket i Norge 2003 - 2007 2009: Legemiddelforbruket i Norge 2004 - 2008 2010: Legemiddelforbruket i Norge 2005 - 2009 2011: Legemiddelforbruket i Norge 2006 - 2010 2012: Legemiddelforbruket i Norge 2007 - 2011 2013: Legemiddelforbruket i Norge 2008 - 2012 2014: Legemiddelforbruket i Norge 2009 - 2013 2015: Legemiddelforbruket i Norge 2010 - 2014 4 Legemiddelstatistikk er av rapporten, og oversatt kun i elektronisk format. En pdf fil av rapporten kan lmfin@fhi.no . Oslo, april 2016 Preface The report Drug Consumption in Norway has been published annually since 1977. The statistics are based on total drug sales from whol esalers. This is the 3 8th edition of the report . It is ma inly organized according to the previous editions and the report is published as a combi ned Norwegian/English edition. The main statistical chapters for each ATC group are only partly translated into English. ATC codes are included for all the substances in order to increase the understanding . The first part of the report includes comments to the total drug cons umption. The present edition includ es data for the period 2011-2015 . The figures are based on sales from all drug wholesalers in Norway and includ e sales of over the counter medicines which are available in non- pharmacy outlets . All wholesalers in Norway report total sales of medicines directly to the Norwegian Institute of Public Health on a monthly basis . A Norwegian P rescription database (NorPD) was from January 2004 established at the Norwegian Institute of Public Health. NorPD includes prescribing information at the individual patient level from all Norwegian pharmacies. NorPD offers more detailed information about the drug use in the population. More information regarding the NorPD is available in a separate annually report and on www.norpd.no . A list of ATC and DDD alterations valid from 1 January 2016 is included on p . 91. For more information on the statistical presentation of drug consumption, p lease confer the introduction. In order to fully understand the statistical material in this book we recommend reading the introduction. This report is available in electronic format only. A pdf file can be downloaded from the website: www.drugconsumption.no or from www.fhi.no . Requests regarding the statistics can be forwarded by email to lmfin@fhi.no . Oslo, April (ATC) classification system ................................ ................................ ....... 7 Units of measurement (Defin ed Daily Dose (DDD) and Costs) ................................ ................................ .............. 8 Evaluation and application of drug statistics based on sales figures from wholesalers ................................ ........ 10 Nordic Statistics ................................ ................................ Sales of OTC medicines outside pharmacies ................................ ................................ .............................. 12 Turnover per ATC main for each A Alimentary tract and metabolism ................................ ................................ ................................ ..................... 21 and blood forming ................................ ................................ ....... 45 H Systemic hormonal preparations, excl. sex hormones and insulins ................................ ................................ 51 J Antiinfectives systemic (1. niv\u00e5), tall for de ulike undergruppene (2., 3. og 4. niv\u00e5) og ned til tall som viser forbruket av det enkelte virkestoff. Introduction The figures in the book represent sales from wholesalers to retailers (pharmaci es, hospitals, nursing homes and non -pharmacies outlets ).The statistics include total sales of medicinal products with marketing authorisation in Norway. It should be emphasised that sales from wholesalers are not necessarily equal to what is actually consumed. The source of the data should always be considered when interpreting and evaluating drug use and the necessary limitations should be included in the conclusions. The statistical tables are sorted according to the ATC classification system, and the Defined Daily Dose are used as the unit of measurement. The ATC/DDD version valid from January 2016 is used in this edition . The A natomical Therapeutic C hemical (ATC) classification system In the ATC system the drug substances are classified into g roups at 5 different levels. The drugs are divided into 14 main groups (1st level), then further divided into pharmacological/ therapeutic subgroup s (2nd level). The 3rd and 4th levels are chemical/ pharmacological /therapeutic subgroups and the 5th level i s the chemical substance . The ATC code A complete classification of spironolactone with the ATC code C03DA01 illustrates the structure of the ATC system: C Cardiovascular system (1st level, anatomical main group) C03 Diuretics (2nd level, therapeutic subgroup) . C03D Potassium -sparing agents (3rd level, pharmacological subgroup) antagonists (4th level, pharmacological subgroup) C03DA 01 Spironolactone (5th level, chemical substance) All products containing spironolactone (Aldact one \u00ae and Spirix\u00ae) are assigned the code C03DA01. The ATC classification system makes it possible to compile drug statistics on 5 different levels, that is, figures showing total consumption of all products classified in main group C - Cardiovascular syst em (1st level), figures for the various subgroups (2nd, 3rd and 4th levels), and down to figures showing consumption of each active ingredient. 8 Legemiddelstatistikk 2016 :1Folkehelseinstituttet ATC som er publisert i Felleskatalogen . WHO Collaborating Centre for Drug Statistics Methodology I 1982 opprettet WHO et koordineringssenter ved NMD i Oslo, WHO Collaborating Centre for Drug Statistics Methodology med tilknytning til WHOs Europakontor i K\u00f8benhavn. med medlemmer fra 12 ulike land. Fra terapitradisjonene kan fra land til et annet preparater ATC code for all pharmaceuticals on the Norwegian market can be found in the monographs of the national drug catalogue Felleskatalogen . The WHO Collaborating Centre for Drug Statistics Methodology In 1982 the WHO Regional Office for Europe established a coordinating centre at NMD in Oslo; the WHO Collaborating Centre for Drug Statistics Methodology . In May 1996 the Centre was attached to the WHO Headquarter in Geneva due to the increasing global use of the ATC/DDD system . The main tasks of the WHO Centre are to classify drugs according to the ATC system, assign Defined Daily Doses and to further develop the ATC/DDD system. This work is performed in close cooperation with a global expert group representing 12 different countries. As from 2002 t he Centre has been located at the Norwegian Institute of Public Health. Units of measurement The Defined Daily Do se (DDD) Prices change with time; prices differ between alternative preparations and between countries. Statistics based on currency is hence difficult to a ssess. Other quantities, independent of price changes and changing exchange rates, may offer a bett er basis for professional evaluations. But, when using quantities such as number of tablets, number of packages etc., comparisons between different drugs used alternatively on the same indications, will often not be possible. The use of DDDs as units of measurement offers better possibilities for comparisons between alternative medicinal products , independent of price differences. The evaluation of drug consumption over time, nationally and internationally, is simplified and improved by the use of DDDs. A DDD is defined as the assumed average maintenance dose per day for a drug used on its main indication in adults . The DDDs are determined on the basis of evaluation of international use of the substance in question, bearing in mind that national therapy traditions (indications, dosages) often differ greatly. Each DDD should therefore be regarded as a technical measuring unit. Drugs used for more than one indication are a challenge. For antipsychotics the doses used in psychoses and not the lower dose s used in the treatment of neuroses, are chosen as the basis for assignment of the DDDs. With the exception of some specific pediatric products , adult dosages are used. The DDD for a substance will often be one and the same, irrespective of the route of administration. Drugs with different bioavailability for different routes of administrations may, however, have more than one DDD, each of them linked to a specific dosage form. For products where a booster dose is followed by a smaller maintenance dosag e, the maintenance dose will form the basis for the DDD. Whenever possible, the DDD is indicated as the quantity of active substance. When this is impossible, as is the case with combination products and some liquid products , the DDD is given as the numb er of unit doses (no of tablets, millilitres etc.). Legemiddelstatistikk 2016 Dette tal let vil gi side 94. Prinsippene av DDD er n\u00e6rmere beskrevet i publikasjonen Guidelines for ATC classification and DDD assignment 2016 , Oslo 2015 . ATC Index with DDDs , en plassert i til grossist til apotek/dagligvare The DDDs are not necessarily the most frequently prescribed or used doses. This must be considered when evaluating the data. Accordingly it will often be difficult to estimate the number of users by u sing the DDD as the measuring unit. The sales figures are given as the number of DDDs/1000 inhabitants/day, calculated as follows: Total consumption measured in DDDs x 1000 3651) x number of inhabitants This figure offers an estimation of what proport ion of the population that may receive a certain drug treatment. An estimated drug consumption of 10 DDDs/1000 inhabitants/day corresponds to a daily use of this drug by 1% of the population. This estimate is, however, only valid if there is good correla tion between the DDD and the actual consumed dose. For some drug groups mainly used during shorter periods, a presentation of the sales data as the number of DDDs/inhabitant/year may be more convenient. An estimated sale of 5 DDDs/inhabitant/year will in dicate that each inhabitant may undergo a treatment of 5 days duration. If the standard treatment lasts 7 days, one may alternatively estimate the number of 7 -day courses by dividing the total number of sold DDDs by the course duration . The DDDs used in this book are for most drugs indicated in adjacent brackets. DDDs for combination products in Norway see page 94. The principles of the ATC /DDD system are more thoroughly described in the publication Guidelines for ATC classification and DDD assignment 2016, Oslo 2015. The ATC I ndex with DDDs includes all assigned D DDs for plain products . Both the Guid elines and the ATC/DDD Index can be ordered from the WHO Centre . The Guidelines and ATC/DDD I ndex are also available from the website of the Centre : www.whocc.no . Sales in DDD For some substances the sale is too low to be given in the statistics. This will be indicated as e.g. 0.00 or 0.0. Costs in Norwegian currency Estimates of the expenditure in NOK for the period 2011-2015 are included in separate tables for each ATC 3rd level. These tables are included in connection with each ATC main group and the costs are expressed in pharmacy retail price (AUP). The calculation of the pharmacy retail price is based on the invoi ced pharmacy purchase price with the addition of the pharmacy margin including fees and VAT. There is no price regulation of non- prescription medicines in Norway and it is therefore difficult to estimate the OTC sales in terms of pharmacy retail prices. The Norwegian Institute of Pu blic Health has no information of the actual retail prices for OTC medicines. The turnover in retail prices is calculate d by using the 1) 366 dager ved skudd\u00e5r / 366 days in leap year 10 Legemiddelstatistikk 2016 :1Folkehelseinstituttet som omregnes til legemiddelbruk i de nor diske land Medicines Consumption in the Nordic Countries 2004- 2008, ble utgitt i 201 0. Publikasjonen fra p\u00e5 samme nettside. purchase prices multiplied with a factor of 2.1. It should be emphasized that the estima ted cost given in pharmacy retail prices in this report probably underestimates the actual cost. Figures from the Norwegian Prescription Database (NorPD) (www.norpd.no ) will give the actual cost in pharmacy retail prices of prescription medicines. Evaluation and application of drug statistics Drug statistics based in sale from wholesalers are important basis for medical and health economic assessments. The statistics can be used to: - survey consumption, and henc e therapy, on different levels and during time - measure the effect of legislative changes and informational efforts - define needs for further investigation of drug therapy traditions The following limitations should however be kept in mind when using the statistics: - all medicaments sold from the wholesalers are not necessarily consumed - sales intended for use in general practice and institutions are not treated separately in this book's statistical material . Nordic Statistics A special publicat ion concerning medicines consumption, Medicines Consumption in the Nordic Countries 2004- 2008, was published in 20 10. The publications can be ordered from the Nordic Medico- Statistical Committee ( Artillerivej 5 , from the we bsite: www.nowbase.org . Figures for 2014 are published in the Health statistics in the Nordic countries 2015 , also available from the website. Legemiddelstatistikk Omsetningen av humane legemidler \u00f8kt e med 8,6 2013 (tabell 2, figur 1) , mens det 2014 og 2015 har v\u00e6rt den st\u00f8rste gruppen og utgjorde 25 % av omsetningen i kroner i 2015 (tabell 1, s. 14). I denne gruppen var kostnadsveksten p\u00e5 7 % i 201 5. Den st\u00f8rste kostnadsveksten p\u00e5 23 % var i ATC til systemisk bruk som inkluderer har v\u00e6rt doser (DDD) og 89 % lt i 1,3 % i 201 5. Reseptfrie legemidler utgjorde 1 3 % av General comments to consumption trends Total sales In 20 15 the total sales of medicinal products with marketing authorisation in Norway totalled 16.1 billion NOK (incl. 1.1 billion for veterinary medicines). The estimated retail cos ts (AUP) was around 24 billion NOK in 201 5. The sale of medicines for human use increased by 8.6% in 201 5 and this increase was similar to the increase in 2014 . The sales fo r the different ATC main gr oups are given in table 1 page 14. The calculation of sales in pharmacy retail price is based on the invoiced pharmacy purchase price added the pharmacy margin, fees and VAT (i.e. using the Norwegian Medicines Agency price formula in calculation of the approved maximum retail price). The estimated costs presented in this book may therefore deviate from real costs especially in groups where special purchase agreements exist e.g. for hospitals or pharmacies where the purchase prices are lower than the approved maximum purchase prices. In these cases, the real pharmacy retail costs may be higher than the estimated pharmacy retail costs (AUP) presented in this book. For prescription medicines, the real costs can be retrieved from the NorPD (www.norpd.no ). In order to reduce reimbursement costs , changes in price regulations have been introduced in Norway. The \"index price\" system was introduced in 2003 and this was replaced by the graded price model in 2005. The graded price model is a stepwise price reduction when generic alternatives are market ed. In addition \"preferred drugs\" have been introduced in some drug groups in different periods in order to reduce costs. All these regulations have limited the cost increase in the period 2010- 2013 (see table 2 and figure 1), while the increase was higher in 2014 and 2015 . The cost increase in the latest years is due to the approval of new very expensi ve medicines (e.g. HCV, cancer and multiple sclerosis ). ATC group L - Antineoplastic and immunomodulati ng agents continues to be the largest group in terms of costs and accounted for 25 per cent of the total cost in 2015 (table 1, p. 1 4). The cost increase in this group was 7% in 201 5. The largest cost increase (23%) was in ATC group J Antiinfectives for systemic use which include s antivirals (ATC group J05) used for treatment of HCV infections (table 1) . The sales volume measured in number of DDDs increased by 2.1% in 201 5. Sale in DDDs has been relatively constant the latest 5 year period (see figure 1). Prescription Only Medicines (POM) The 2015 POM t urnover amounted to 87% of total number of DDDs and 89 % of sales in terms of cost (AUP) . These fractions have remained relatively constant over time. Non- prescription medicines (OTC) The sales measured in DDDs for OTC medicines 12 Legemiddelstatistikk 2016 :1Folkehelseinstituttet DDD solgt i dagligvar ehandelen \u00f8kte fra 4 9 % i 201 4 til 52 % i 2015 (tabell 3) . 2015 andelen solgt . pakninger av ibu profen i DDD gikk ned med 1 % i 201 5, mens t otalt salg av over tid. av nesesprayer (oksymetazolin og xylometazolin) \u00f8kte med 6 % i 2015 i forhold til i 2014. For de mest ble % til % i 201 5 (tabell 3) decreased by 1.3% in 20 15. OTC medicines accounted for 13% of total sales measured in DD Ds and about 11 % of total costs (AUP) . These proportions have remained unchanged over time. In 20 15 the total sales of OTC medicines increased by around 8% and amounted to around 1.2 billion NOK (pharmacy purchase prices). Since there is no price regulation for OTC medicines, it is difficult to measure the actual cost in pharmacy retail prices (AUP) based on sales from wholesalers. For estimation of AUP for OTC medicines see page 9. Sales of OTC medicines outside pharmacies Retail sale for some nicotine replacement medicines was allowed outside pharmacies from January 2003. From November 2003 this regulation was extended to include a selection of other OTC medicines according to a list issued by the Norwegian Medicines Agency. From 2009 the selection of medicines in non - pharmacy outlets was extended to also include emergency contraception, allergy medicines, hydrocortisone dermatologicals and agents used for treatment of dyspepsia/heartburn . The non -pharmacy outlets still sell only a limited number of drugs. Table 3, p. 16, shows the sales of OTC medicines and the proportion of sales in non-pharmacy outlets in 2011- 2015. This table includes the top selling medicines available also in non- pharmacy outlets . The sale in number of DDDs of the top selling drugs in non-pharmacy outlets increased by 3% in 2015. The non-pharmacy section accounted for 49% of this sale in DDDs in 201 4 while the share increased to 52% in 20 15 (table 3). Trends 2011-2015 Analgesics Sales of OTC paracetamol measured in DDD, increased by 1.4% in 2015 while the share sold in non-pharmacy outlets was at 54% (Table 3). The OTC sale figure corresponds to 35 tablets per inhabitant. Total sales of paracetamol (prescription a nd OTC) increased by 4 percent in 2015. Figure 2 shows the trend in total sales of paracetamol in the period 2003-2015. OTC accounted for a share of 41 percent of total sales of paracetamol in 2015 and this proportion has declined over time. Total number of DDDs for OTC formulations of ibuprofen decreased by 1% in 201 5 while the total sales of ibuprofen remained unchanged. In 20 15 the fraction of OTC sales of ibuprofen i n terms of DDDs was 54 % the total sale. Nasal decongestants The sales in DDDs of ox ymetazo line and xylometazoline increased by 6% in 2015 . The sales of xylometazoline in non -pharmacy outlets have increased over t ime and in 2015 the share was 67 %. The proportion of sale in non- pharmacy outlets of the combination product of xylometazoline and ipratropiumbromide (R01AB06) increased to 35% in 2015 (table 3). Legemiddelstatistikk 13 Legemidler med niko tin r\u00f8ykeavvenningsmidler ble 000 doser n\u00f8dprevensjon i 2015 hvorav 9 700 (7 %) ble solgt i dagligvare . cetirizin m\u00e5lt i DDD redusert med % i 2015, mens andel solgt i dagligvarehandelen \u00f8kte til 1 (s. 14) gir en over salg i 201 5 per legemiddelgruppe i millione r doser (DDD) og i millioner kroner (AIP). ATC gruppe L - Antineoplastiske og immunmodulerende midler utgjorde 2 5 % av totalomsetningen av humane legemidler i 2015 og er den gruppen som har st\u00f8rst omsetning i kroner. \u00d8kningen i kroner var p\u00e5 7 % som er lavere tidligere gjort noen leg St\u00f8rst \u00f8kning m\u00e5lt i kroner i 2015 - Antiinfektiva til systemisk bruk hvor \u00f8kningen var p\u00e5 23 av kostbare st\u00f8rst e legemiddelgruppen I 2015 var den prosentvise \u00f8kningen i ATC gr C i antall DDD me ns har \u00f8kt (se figur side 39). Nicotine replacement products The sale measures in DDDs of nicotine replacement products increased by 10% in 20 15. The non - pharma cy share has gradually increased and the share was 47% in 2015. Emergency contraceptives A total of 141 000 doses was sold in 201 5 and of these 9 700 doses ( 7%) was sold in non -pharmacy outlets. Two OTC produ cts are available in Norway : Norlevo\u00ae (levonorgestrel) and Ellaone\u00ae (ulipristal ). Only levonorgestre l was available in in non -pharmacy outlets in 2015, while sales of ulipristal has been allowed in non -pharmacy outlets from February 2016. Total s ale of emergency contraceptives was stable in 2015 compared to 2014. Antihistamines Sales in DDDs of OTC packages of cetirizine decreased by 14% in 2015 . The share sold in non- pharmacy outlets increased to 26% (table 3) . Other medicines The sales of expectoran ts and motion sickness tablets in non -pharmac y outlets are given in table 3. Apart from the medicines lis ted in the table, a selection of other agents including vitamins and wound healing medicines are also available in non -pharmacy outlets . Turnover per ATC main group The 20 15 sales per ATC main group measured in million DDDs and in million NOK, pharmacy purchase price (AIP) are given in table 1 (p. 14). ATC group L - Antineoplastic and immunomodulating agents, has had a gradual increasing share of total sales which can be explained by increased use of high cost medicines for use in ca ncer treatment and increased sal es of biological medicines (ATC group L04) for the treatment of e.g. rheumatoid arthritis. ATC group L had a share of 25% of total costs of human medicines in 20 15 and was the largest group in terms of cost. The largest increase in cost in 2015 was in ATC group J - Antiinfectives for systemic use where the increase was 23% in 2015 . Introductions of new antivirals for treatment of hepatitis C infections highly influence the cost in this group. ATC group C - Cardiovascular system is the larges t group in term of sales in DDDs (table 1). Prevention of cardiovascular diseases is important. Treatment of hypertension and hypercholesterolemia reduce s the risk of ischemic heart disease s. In 2015, the percentage sale increase in number of DDDs in ATC gr C was 1.6, whi le cost increase was 2.3 %. ATC group C has had a gradually decreasing share of total costs, which is explained by the introduction of pricing/reimbursement regulations. The sales of cholesterol reducing agents in DDDs increased by 5% in 2015. The used of statins increased as well as the use of fixed combinations of statins and ezetimibe (see figure page 39). New therapies for treatment of pulmonary arterial hypertension have also contributed to the increased cost in ATC group C. 14 Legemiddelstatistikk 2016 :1Folkehelseinstituttet \u00d8kt salg av har ogs\u00e5 bidratt til kostnadsvekst en i ATC gruppe C. Salg i ATC gruppe Q - Veterin\u00e6re legemidler \u00f8kte med Sales i n ATC group Q - Veter inary medicines increased by 8% in 201 5. This group includes veterinary vaccines and most agents used in fish farming. Tabell 1. Salg av legemidler med markedsf\u00f8ringstillatelse per ATC hovedgruppe i 201 5 og endringer i forhold til 2014 . Salg i kroner i pris fra grossist (AIP) Table 1. Sales of drugs per ATC main gro up in 2015 and changes from 2014 . Sales in NOK in pharmacy purchase price (AIP) ATC hovedgruppe ATC main group Salg i mill DDD Sales in mill DDD Endring i mill DDD Change in mill DDDs % endring i DDD % change in DDDs Salg mill kr (AIP) av totale kostnader (ekskl ATC Q) % share of total cost human medicines L - Antineoplastic and immunomod.1) 35 1 4,4 3 773 244 6,9 25,2 N - Nervous system 427 7 1,7 2 352 141 6,4 15,7 J - Antiinfectives for 1 594 22,5 15 3,1 1 411 115 8,8 9,4 B - Blood and blood forming organs 229 - 0,5 -0,2 1 286 141 12,3 8,6 R - Respiratory system 372 10 2,7 1 234 44 3,7 8,2 C - Cardiovascular system 775 12 1,6 922 21 2,3 6,1 G - 46 6,7 4,8 M - Muscul o-skeletal system 116 3 2,4 464 52 12,6 3,1 H - Systemic hormonal preparations 86 1 1,5 377 23 6,5 2,5 S - Sensory organs2) 1,4 2,4 1,9 191 products, etc.3) 26 -1 -3,8 0,2 Sum human medicines 2 824 58 2,1 14 994 1 183 8,6 100 Q - Veterinary medicines3) 1 090 79 7,9 Total 2 824 58 2,1 16 084 1 262 8,5 1) DDDs are only assigned for some drugs. 2) DDDs are only assigned for antiglaucoma preparations. 3) DDDs are not assigned for veterinary medicines (ATC Q) and only for some drugs in ATC group D, P and V. Legemiddelstatistikk 2016 :1Folkehelseinstituttet 15 Tabell 2. Sales in billion NOK (AUP) o f medicinal products 2003 - 2015 (excl veterinary medicines) \u00c5r Year Milliarder kr og DDD 2005 - 2015 Figure 1. Per cent annual change in total sales excl veterinary medicines measure d in NOK (AUP ) and DDDs 2005 - 2015 -4 -2 0 2 4 6 8 10 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 Prosent (%) DDD AUP 16 dagligvare og apotek, 2011 - 2015 Table 3. Sales of the main OTC medicines available both in non -pharmacy outlets and in pharmacies , 2011 - 2015 ATC og v irkestoff Active ingredient Bruksomr\u00e5de Indication Sales in DDD/1000 inhabitants/day (% share in non- pharmacy outlets ) 2011 2013 2014 2015 (ibuprofen) og side 7 2 (paracetamol). Excluding sales of prescription only packages. Total sales see tables on page 68 (ibuprofen) and page 72 (paracetamol) 2) Solgt kun fra februar 2011. No sale outside pharmacies. Legemiddelstatistikk 2016 :1Folkehelseinstituttet 17 les in DDD/1000 inhabitants/day paracetamol (OTC and POM packages) in pharmacies and non- pharmacy outlets 2003- 2015 0 5 10 15 20 25 30 35 40 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 DDD/1000 1. januar Population 920 305 368 576 424 638 192 810 259 309 1 678 123 1 359 812 415 884 870 372 438 424 921 191 488 259 718 1 703 611 1 379 093 433 275 375 014 426 509 190 264 261 666 1 728 068 1 396 542 109 056 375 744 428 077 190 040 262 789 1 744 961 1 408 723 477 962 220 760 824 191 844 221 768 96 701 135 324 904 396 726 741 240 526 81 524 Menn 2 566 978 182 110 211 810 92 185 127 157 855 117 697 908 261 778 138 913 Totalt antall 5 165 802 373 954 433 578 188 886 262 481 1 759 513 1 424 649 502 EphMRA European Pharmaceutical Market Pharmacy purchase price ATC Anatomical Therapeutic Chemical Classification AUP Pharmacy retail price (estimated) DDD Defined Daily D ose ED Unit dose EphMRA European Pharmaceutical Market Research Association MU Million units N (adm.form) Nasal NorPD Norwegian Pre scription Dat abase O (adm.form) the counter\", non prescription drugs P (adm.form) Parenteral PDD Prescribed daily dose POM Prescription only (adm.form) Rectal SL (adm.form) Sublingual TD (adm.form) Transdermal TU Thousand units U Units UD Unit dose V (adm.form) Vaginal ATC gruppe A Legemiddelstat istikk 201 6:1Folkehelseinstituttet 21 Ford\u00f8yelsesorganer og stoffskifte A01 - og tannmidler Stomatological preparations (not included) A02 Midler mot syrerelaterte lidelser Drugs for acid related disorders A03 Midler mot lidelser A11 (utelatt) included) Andre ford\u00f8yelses - og stoffskiftepreparater Other alimentary tract and metabolism products ATC gruppe A 22 Legemiddelstatistikk 2016 :1Folkehelseinstituttet Salg pr ATC 3. niv\u00e5 for gruppe A - Ford\u00f8yelsesorganer og stoffskifte Sales per ATC 3rd level for ATC group A - Alimentary tract and metabolism mill NOK (AUP) ATC ATC level name 2011 2012 23 DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2011 2012 2013 2014 2015 A02 Salg av magnesiumforbindelser er ikke med. Sales of magnesium compounds (ATC group A02AA) are not included. 2) No DDD is assigned by the WHO Collaborating Centre for Drug Statistics Methodology. The DDDs used in the table are nation al DDDs for Norway. 3) DDD for kombinasjonen er lik DDD for famotidin. The DDD for the combination is equivalent to the DDD for famotidine. Avregistrert 01.11.2014. ATC gruppe A 24 Legemiddelstatistikk 2016 :1Folkehelseinstituttet av midler mot ulcus og GORD (A02B) 1990 -2015 Sales of drugs for ic ulcer and GORD (A02B) 1990 -2015 DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2011 2012 2013 2014 2015 A03 0 5 10 15 20 25 30 35 40 45 50 55 1990 1992 1994 1996 1998 2000 2002 2004 2006 2008 2010 2012 2014 DDD/1000 inhabitants/day 25 DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2011 2012 2013 2014 2015 A05 Galle helsekostforretninger. 2) Omfatter kun salg 26 Legemiddelstatistikk 2016 :1Folkehelseinstituttet DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2011 2012 2013 2014 2015 A07E 27 DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2011 2012 2013 2014 2015 name (DDD value) 2011 2012 2013 2014 2015 A16 Andre DDD ikke 28 6:1Folkehelseinstituttet 29 Blod bloddannende og infusjonsl\u00f8sninger ol. (kun salg i kroner) Blood substitutes and perfusion solutions (sales in NOK only) B06 Andre hematologiske hematological agen ts pr for gruppe B - Blod og bloddannende organer Sales per ATC 3rd level for ATC group B - Blood and blood forming organs mill NOK (AUP)1) ATC ATC level name 2011 2012 2013 gruppe B 30 Legemiddelstatistikk 2016 :1Folkehelseinstituttet DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2011 2012 2013 2014 2015 DDDs/year ATC ATC level name (DDD value) 2011 2012 2013 2015 1284 1273 1650 DDD/1000 inhabitants/day ATC ATC level name (DDD 91 . B Legemiddelstat istikk 201 6:1Folkehelseinstituttet 31 DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2011 2012 DDDs/year ATC ATC level name (DDD value) 2011 2012 2013 2014 2015 B06 Andre hematologiske 992 B06AC04 Conestat alfa (3,5 TU) 5 22 11 1) B02B Vitamin K og andre hemostatika er utelatt. 2) Inkluderer av folsyre avregistrert i september 2014. Legemiddelstat istikk renin -angiotensin system C10 Lipidmodifiserende midler Lipid modifying agents ATC gruppe C 34 Legemiddelstatistikk 2016 :1Folkehelseinstituttet Salg pr ATC 3. niv\u00e5 for gruppe C - Hjerte og kretsl\u00f8p Sales per ATC 3rd level for ATC group C - Cardiovascular system mill NOK (AUP) ATC ATC level name 2011 2012 2013 2014 35 DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2011 2012 36 Legemiddelstatistikk 2016 :1Folkehelseinstituttet DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2011 2012 2013 2014 2015 istikk 201 6:1Folkehelseinstituttet 37 DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2011 2012 2013 2014 2015 C09 Midler of antihypertensives (C02), diuretics (C03), beta blocking agents (C07) calcium channel blocker s (C08) and ACE inhibitors/angiotensin II antagonists (C09) 1990 -2015 DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2011 2012 2013 2014 2015 C10 Lipidmodifiserende uten markedsf\u00f8ringstillatelse i Norge. 0 20 40 60 80 100 120 140 160 180 200 220 240 260 280 300 1990 1992 1994 1996 1998 2000 2002 2004 2006 2008 2010 2012 2014 DDD/1000 inhabitants/day of statins and ezetimibe incl. combinations 1990 - 2015 given in DDD/1000 inhab./day 0 20 40 60 80 100 120 140 1990 1992 1994 1996 1998 2000 2002 2004 2006 2008 2010 2012 2014 DDD/1000 protecti ves D03 Midler til s\u00e5rbehandling Preparations for of preparations legemidler i ATC gruppe D er til dermatologisk bruk. disse legemidlene. Most of the drugs in ATC group D are for topical use. Only a few oral preparations are given DDDs. Detailed consumption figures are only included for these preparations. ATC gruppe D 42 Legemiddelstatistikk 2016 :1Folkehelseinstituttet Salg pr ATC 3. niv\u00e5 for gruppe D - Dermatologiske midler Sales per ATC 3rd level for ATC group D - Dermatologicals mill NOK (AUP) ATC ATC level name 2011 2012 2013 2014 2015 D01A Antifungals 43 DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2011 2012 2013 2014 2015 D01 effekt genitalia G04 Urologika Urologicals Salg pr ATC 3. niv\u00e5 for gruppe G - Urogenitalsystem og kj\u00f8nnshormoner Sales per ATC 3rd level for ATC group G - Genito urinary system and sex hormones mill NOK (AUP) ATC ATC level name 2011 2012 2013 2014 2015 G01A Antiinfectives :1Folkehelseinstituttet DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2011 2012 2013 2014 2015 G01 numbers of vaginal rings ATC ATC level name 2011 2012 2013 2014 2015 name 2011 2012 2013 2014 2015 G03 Kj\u00f8nnshormoner 1) Se ogs\u00e5 ATC gr. P01AB og J01XD. See also ATC er ikke tatt med. 4) The vaginal ring should be replaced every 28 day. This implies that each user needs 13 vaginal rings per year. 5) Ekskl. salg av implantater. Excluding sales of implants. 6) Salg angitt i antall implantater. Sales given in number of ATC gruppe G Legemiddelstat istikk 201 Salg av P -piller, prevensjonsplaster og n\u00f8dprevensjon (G03A) 1990 - 2015 Sales of oral and transdermal hormonal contraceptives (G03A) 1990 - 2015 DDD/day ATC ATC level name (DDD value) 2011 2012 2013 (2 mg) 1994 1996 1998 2000 2002 2004 2006 2008 2010 2012 2014 DDD/day preparater (G03C and G03F) 1990 -2015 DDD/day ATC ATC level name (DDD value) 2011 2012 2013 2014 2015 G03G 390 330 G03GA02 Menopausego nadotropin (75 U) 180 230 240 260 290 G03GA04 Urofollitropin (75 U) 20 30 30 60 10 G03GA05 Follitropin alfa (75 U) 200 200 200 190 270 G03GA06 Follitropin beta (75 U) 250 210 200 180 170 G03GA08 Koriongonadotropin alfa (0,25 mg) 21 24 25 603 13 13 13 13 13 G03XB02 Ulipristal (5 mg) 3 64 280 G03XC01 Raloxifen (60 mg) 820 720 610 340 310 1) ATC code G03GA07, G03GA09 and G03GA30 are not included due 1994 1996 1998 2000 2002 2004 2006 2008 2010 2012 2014 49 DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2011 2012 ATC ATC level name (DDD value) 2011 2012 2013 2014 2015 G04BE Papaverin/fentolamin1) 35 13 13 15 14 DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2011 2012 2013 2014 2015 G04C Midler 2016 systemisk bruk, ekskl kj \u00f8nnshormoner og insuliner Sales per ATC 3rd level for ATC group H - Systemic hormonal preparations, excl sex hormones and insulins mill NOK (AUP) ATC ATC level name 2011 2012 2013 2014 2015 H01A Anterior :1Folkehelseinstituttet DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2011 2012 2013 2014 2015 H01 53 Salg av levotyroxinnatrium (H03AA01) 1990 - 2015 Sales of levothyroxine sodium (H03AA01) 1990 - 2015 DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2011 2012 5 10 15 20 25 30 1990 1992 1994 1996 1998 2000 2002 2004 2006 2008 2010 2012 2014 DDD/1000 inhabitants/day 54 Legemiddelstatistikk 2016 :1Folkehelseinstituttet ATC Vaccines (not included) Salg pr ATC 3. niv\u00e5 for gruppe J - Antiinfektiva til systemisk bruk Sales per ATC 3rd level for ATC group J - Antiinfectives for systemic use mill NOK (A UP) ATC ATC level name 2011 2012 2013 :1Folkehelseinstituttet DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2011 2012 2013 2014 2015 J01 istikk 201 6:1Folkehelseinstituttet 57 DDD/10 00 inhabitants/day ATC ATC level name (DDD value) 2011 2012 2013 2014 2015 J01X antibacterials systemic use (J01) 1990 - 2015 1) Se ogs\u00e5 ATC gruppe A07AA, see also ATC group A07AA. 2) Se ogs\u00e5 ATC gruppe G01AF og P01AB, see also ATC group G01AF and P01AB. 0 5 10 15 20 25 1990 1992 1994 1996 1998 2000 2002 2004 2006 2008 2010 2012 2014 DDD/1000 inhabitants/day J01 J01C :1Folkehelseinstituttet DDD/1000 inhabitants/year ATC ATC level name (DDD value) 2011 2012 2013 2014 2015 istikk 201 6:1Folkehelseinstituttet 59 DDD/1000 inhabitants/year ATC ATC level name (DDD value) 2011 2012 for gruppe L - Antineoplastiske og immunmodulerende midler Sales per ATC 3rd level for ATC group L - Antineoplastic and immunomodulating agents mill NOK (AUP)1) ATC ATC level name 2011 2012 2013 i Norge. ATC gruppe L 62 Legemiddelstatistikk 2016 :1Folkehelseinstituttet gram of active ingredient/year ATC ATC level name 2011 2012 2013 66 71 74 73 94 75 66 98 108 160 L01AD04 Streptozocin Kladribin 2 3 3 3 3 L01BB05 Fludarabin 126 103 108 102 100 L01BB06 Klofarabin 3 2 1 0 1 L01BB07 Inkluderer preparater L04AX03. ATC gruppe L Legemiddelstat istikk 201 6:1Folkehelseinstituttet 63 gram of active ingredient/year ATC ATC level name 2011 2012 2013 2014 2015 Ofatumumab 20 12 34 L01XC11 Ipilimumab 2 65 115 101 L01XC12 Brentuximabvedotin 6 6 6 L01XC13 Pertuzumab 4 TU (tusen enheter) virkestoff/\u00e5r . Sales given TU (thousand units)/year . ATC gruppe L 64 Legemiddelstatistikk 2016 :1Folkehelseinstituttet gram of active ingredient/year ATC ATC level name 2011 2012 2013 triokside 1 3 3 L01XX32 Bortezomib 20 22 26 29 28 L01XX35 Anagrelide 86 83 83 91 102 L01XX41 Eribulin 0 0 2 2 2 enheter) virkestoff/\u00e5r Sales given in (thousand units)/year L Legemiddelstat istikk 201 6:1Folkehelseinstituttet 65 DDD/1000 inhabitants/year ATC ATC level name (DDD value) 2011 2012 Poly\u00f8stradiolfosfat (6 mg) 0 0 Progestogener 8 6 6 5 6 L02AB01 Megestrol (0,16 8 6 6 5 6 627 615 606 582 560 L02AE01 Buserelin (0,11 mg depot implant/1,2 mg N) 14 9 10 5 3 L02AE02 Leuprorelin (0,134 mg depot 223 L02AE03 313 320 334 L02AE04 Triptorelin (0,134 mg) 0 0 0 274 L02BA01 Tamoxifen (20 mg) 216 191 279 254 251 L02BA03 Fulvestrant (8,3 mg) 23 21 20 9 824 828 g) 473 490 506 545 L02BG03 Anastrozol (1 mg) 147 112 86 69 58 L02BG04 Letrozol ( 2,5 mg) 285 316 357 389 436 L02BG06 Eksemestan (25 mg) 51 45 47 48 51 L02BX Andre hormonantagonister og beslektede substanser 16 37 51 63 67 L02BX02 Degarelix (2,7 mg) 15 21 26 34 42 L02BX03 1 16 25 29 25 L03 348 345 315 248 205 348 345 315 248 205 L03AA02 Filgrastim mg) 4 4 5 5 4 L03AA13 Pegfilgrastim (0,3 mg) 31 35 128 91 66 L03AB08 Interferon beta -1b (4 MU) 36 36 34 25 18 L03AB10 Peginterferon alfa -2b (7,5 mcg) 15 L03AB11 Peginterferon alfa -2a (26 mcg) 16 -1a (8,9 mcg) L03AX03 BCG vaksine 6 6 7 7 7 L03AX13 Glatiramer acetat (20 mg) 68 73 68 52 40 L03AX16 Plerixafor (16,8 mg) 0 0 0 0 0 1) Inkluderer salg av preparater uten markedsf\u00f8ringstillatelse i 66 Legemiddelstatistikk 2016 :1Folkehelseinstituttet DDD/1000 inhabitants/ year ATC ATC level name (DDD value) 2011 2012 2013 2014 209 218 L04AA10 Sirolimus (3 mg) 10 9 10 10 11 L04AA13 Leflunomid (20 mg) 76 78 84 90 97 L04AA18 Everolimus (1,5 mg) 35 42 46 47 48 L04AA23 Natalizumab (10 mg) 45 54 58 57 56 L04AA24 Abatacept (27 mg) 8 8 7 285 294 270 L04AB05 Certolizumab pegol (14 mg) 14 28 56 141 177 L04AB06 Golimumab (1 ,66 mg) 67 66 102 122 125 L04AC Interleukinhemmere 27 40 53 79 7 L04AC05 Ustekinumab (0,54 mg) 9 15 24 44 58 L04AC07 Tocilizumab (20 mg) 13 19 23 282 291 L04AD01 Ciklosporin (0,25 g) 160 149 140 132 129 L04AD02 Tacrolimus (5 mg) 106 130 139 150 312 L04AX02 Thalidomid (0,1 g) 10 products for joint midler Muscle relaxants til behandling av bensykdommer Drug s for treatment of bone diseases M09 Andre midler mot muskel - og skjelettsykdommer Other drugs for disorders of the musculo -skeletal system Salg pr ATC 3. niv\u00e5 for gruppe M - Muskler og skjelett Sales per ATC 3 rd level for ATC group M - Musculo -skeletal system mill NOK (AUP) ATC ATC level name 2011 2012 2013 2014 2015 M01A Antiinflammatory and See also ATC group N02B . ATC gruppe M 68 Legemiddelstatistikk 2016 :1Folkehelseinstituttet DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2011 2012 2013 2014 2015 M01 of antiinflammatory and antirheumatic products, non -steroids (M01A) 1990 - 2015 0 10 20 30 40 50 60 1990 1992 1994 1996 1998 2000 2002 2004 2006 2008 2010 2012 2014 DDD/1000 inhabitants/day Total 69 DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2011 2012 2013 2014 2015 M03 indikasjoner. for on 70 Legemiddelstatistikk 2016 :1Folkehelseinstituttet ATC gruppe N Legemiddelstat istikk for gruppe N - Nervesystemet Sales per ATC 3rd level for ATC group N - Nervous system mill NOK (AUP) ATC ATC level name 2011 2012 2013 2014 N01A Anesthetics, general Se group M01. 2) Omfatter bare legemidler med mar kedsf\u00f8ringstillatelse i Norge. ATC gruppe N 72 Legemiddelstatistikk 2016 :1Folkehelseinstituttet DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2011 acid products intended for use in thrombosis prophylaxis are classified in B01AC, and accordingly not include d in this table. 4) Kombinasjoner med paracetamol og kodein er klassifisert i 2015 Total sales of analgesics, incl. OTC and prescription only packages 1990 - 2015 DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2011 2012 markedsf\u00f8ringstillatelse i Norge. 0 5 10 15 20 25 30 35 40 1990 1992 1994 1996 1998 2000 2002 2004 2006 2008 2010 2012 :1Folkehelseinstituttet DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2011 75 DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2011 2012 76 Legemiddelstatistikk 2016 :1Folkehelseinstituttet DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2011 2012 2013 2014 2015 N06B Psykostimulantia, av legemidler uten markedsf\u00f8ringstillatelse. 0 10 20 30 40 50 60 70 1990 1992 1994 1996 1998 2000 2002 2004 2006 2008 2010 2012 2014 77 DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2011 2012 2013 2014 2015 N07 Andre pr for gruppe P - Antiparasit\u00e6re midler, insekticider og insektmidler Sales per ATC 3rd level for ATC group P - Antiparasitic products, insecticides, and repellents mill NOK (AUP) ATC ATC level name 2011 2012 2013 2014 2015 P01A Agents against amoebiasis :1Folkehelseinstituttet DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2011 2015 P01 packages ATC ATC 2011 2012 2013 2014 2015 P03 Respirasjonsorganer airway disea ses R05 Hoste - og forkj\u00f8lelsesmidler systemisk p\u00e5 respirasjonssystemet Other respiratory system products Salg pr ATC 3. niv\u00e5 for gruppe R - Respirasjonsorganer Sales per ATC 3rd level for ATC group R - Respiratory system mill NOK (AUP) ATC ATC level name 2011 2012 2013 2014 2015 R01A Decongestants and other nasal :1Folkehelseinstituttet DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2011 Legemiddelstat istikk 201 6:1Folkehelseinstituttet 83 DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2011 2012 2013 2014 2015 R03B Andre midler til bruk ved obstruktiv lungesykdom (R03) 1990 -2015 Sales of obstructive airway diseases (R03) 1990 -2015 DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2011 2012 2013 2014 2015 R05 0 10 20 30 40 50 60 70 1990 1992 1994 1996 1998 2000 2002 2004 2006 2008 2010 2012 2014 DDD/1000 inhabitants/day 85 DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2011 2012 2013 2014 2015 \u00f8remidler (kun i and otological preparations (sales in NOK only) Salg pr ATC 3. niv\u00e5 for gruppe S - Sanseorganer Sales per ATC 3rd level for ATC group S - Sensory organs mill NOK (AUP) ATC ATC level name 2011 2012 :1Folkehelseinstituttet DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2011 volum av endosebeholder. The DDDs are based on administration frequencies and single dose. A single dose corresponds to 0.1 ml or the volume of one package (for single use packages). 2) Omfatter salg av preparater uten markedsf\u00f8ringstillatelse i Diagnostic agents (not included) V06 (not included) pr ATC 3. niv\u00e5 for gruppe V - Varia Sales per ATC 3rd level for ATC group V - Various mill NOK (AUP)1) ATC ATC level name 2011 2012 Allergens 36,1 Number of packages/year ATC av 90 Legemiddelstatistikk 2016 :1Folkehelseinstituttet DDD/1000 inhabitants/day ATC ATC level name (DDD value) 2011 2012 2013 2014 2015 niv\u00e5er der DDD er fastsatt er tatt med. Only ATC levels where DDDs are assigned are included. Legemiddelstat istikk 201 6:1Folkehelseinstituttet 91 Alterations in ATC codes and DDDs valid fr om January 2016 Alterations in ATC codes and DDDs valid from Januar y 201 6 are listed below. A cumulative list showing all the ATC/DDD alterations made is also available on the website: www.whocc.no ATC alterations: Previous ATC code ATC level name New ATC code A12AA12 calcium acetate V03AE07 B03AB06 ferric citr ate V03AE08 DDD alteration: ATC code level name Previous DDD New DDD B01AE07 dabigatran etexilate 0.22 g O 0.3 g O B01AF01 rivaroxaban 10 mg O 20 mg O B01AF02 apixaban 5 mg O 10 mg O G03GA02 human menopausal gonadotrophin 30 U P 75 U P 92 Legemiddelstatistikk 2016 :1Folkehelseinstituttet Definerte d\u00f8gndoser er benyttet i statistikken. En liste med alle fastsatte DDD fra Nasjonalt fol kehelseinstitutt vagitorie osv - for pulver til bruk er 1 ED lik 1 gram Dersom DDD for pulver for oralt bruk er 1 ED lik 1 dosepulver - for pulver til injeksjon er 1 ED lik 1 gram pulver. Dersom DDD for pulver til injeksjon substans. - for pulver til inhalasjon er lik 1 ED lik 1 dose pulver f.eks en kapsel - for flytende preparater til oralt bruk er 1 ED lik l\u00f8sning. - for flytende preparater til parenteralt bruk er 1 ED lik 1 ml l\u00f8sning. - for flytende preparater til inhalasjon er 1 ED lik 1 ml l\u00f8sning. - for flytende preparater til rektalt bruk er 1 ED lik 1 ml l\u00f8sning. - for klyster er 1 ED lik 1 klyster. - for plaster for transdermal applisering er 1 ED lik 1 plaster. - for vaginal krem er 1 ED lik 1 dose, 1 applisering. I enkelte tilfeller er administrasjonsform angitt bak Defined daily doses General description, see page 8. Plain preparations The DDDs used in the calculations of the statistics are indicated in brackets after the substance for almost all plain substances. ATC/DDD version valid from January 201 6 is used in the statistics in this book. A list of all the assigned DDDs ( ATC classification index with DDDs) can be ordered from the Norwegian Institute of Public Health, WHO Collaborating Centre for Drug Statistics Methodology, P.O.Box 4404 Nydalen, 0403 Oslo, Nor searchable version of the ATC/DDD index is also available on the website: www.whocc.no. Combined preparations For combined preparations or preparations where a DDD for various reasons cannot be given in amount of active ingredient, the unit UD (unit dose) is used. The Norwegian term ED is used in the list . - Tablets, suppositories, pessaries, etc; 1 UD equals 1 tablet, 1 suppository, 1 pessary etc. - Powder for oral use: 1 UD equals 1 gram of powder. If the DDD for an oral powder is given in grams, this refers to the content of active ingredient. - Powder in single dose units for oral use: 1 UD equals 1 dose powder - Powder for injection: 1 UD equals 1 gram of powder. If the DDD for powder for injection is given in grams, thi s refers to the content of active ingredient - Powder for inhalation 1 UD equals 1 unit dose powder e.g. 1 capsule - Liquid preparations for oral use (mixtures, syrups etc.): 1 UD equals 5 ml of the preparation. - Liquid preparations for parenteral use (injections): 1 UD equals 1 ml of the preparation. - Liquid preparations for inhalation: 1 UD equals 1 ml of the preparation. - Liquid preparations for rectal use: 1 UD equals 1 ml of the preparation. - Enemas: 1 UD equals 1 enema. - Plaster for tran sdermal application: 1 UD equals 1 plaster. - Vaginal cream: 1 UD equals 1 dose, 1 application. = oral P = parenteral R = rektal SL = sublingual/buckal/oromukosal TD = transdermal V = vaginal Route of administration The route of administration is indicated by the following codes: Inhal = inhalation N = nasal O = oral P = parenteral R = rektal SL = sublingual/buccal/oromucosal TD = transdermal V = vaginal . 94 Legemiddelstatistikk 2016 :1Folkehelseinstituttet Preparater der DDD er angitt i ED (enkeltdoser) Products with DDDs expressed in UD (Un it dose) ATC kode ATC code Preparatnavn Product name Doseringsform Dosage form Galieve Gaviscon tyggetabl mikst, tyggetabl Senokot X-Prep tabl Pico-Salax dosepulv ED 1 ED = 274 g pulver 2 ED 4 ED 2 ED 10 ED ED 6 ED 6 ED 4 ED 4 ED 4 ED 4 ED 6 ED 3 ED 6 ED 4 ED A10BD03 Avandamet tabl kode ATC code Preparatnavn Product name Doseringsform Dosage form ED 2 ED A12CC30 Nycoplus Magnesium tygget C07BB07 Lodoz tabl 1 ED tabl 1 ED 1 1 ED C09BA03 1 ED ED C09BA15 Zofenil comp tabl 1 ED C09DA02 Teveten comp tabl 1 ED 1 ED C09DA07 Actelsar Micardis plus tabl tabl kode ATC code Preparatnavn Product name Doseringsform Dosage C10AX06 tabl (21) tabl (28) tabl (28) tabl (21) 0,75 ED 1 ED 1 ED 0,75 ED 1 ED 1 ED 0,75 Synfase ATC kode ATC code Preparatnavn ED G03FA12 Indivina 8 ED 4 ED 20 ED 8 ED 4 ED 20 ED 8 ED 4 ED :1Folkehelseinstituttet ATC kode ATC code Preparatnavn Product name Doseringsform Dosage J05AR13 ED 4 ED 2 ED 8 ED 3 ED 2 ED N02AC54 Aporex tabl N02BB54 Fanalgin tabl 6 4 ED inhal kode ATC code Preparatnavn Doseringsform Dosage form 6 ED 6 ED R05DA20 Sterk 4 ED www.fhi.noLegemiddelforbruket i Norge Consumption in Norway 2011-2015 Utgitt av F olkehelseinstituttet Published by Norwegian Institute of Public Health Bestilling/Order: Kun tilgjengelig som PDF. Lastes ned fra www.fhi.no as PDF from "}